Science News
from research organizations

Drug helps control involuntary, sudden movements of Huntington disease

Date:
July 5, 2016
Source:
JAMA - Journal of the American Medical Association
Summary:
A new study evaluated the efficacy and safety of the drug deutetrabenazine to control a prominent symptom of Huntington disease, chorea, which is an involuntary, sudden movement that can affect any muscle and flow randomly across body regions. Chorea can interfere with daily functioning and increase the risk of injury.
Share:
FULL STORY

In a study appearing in the July 5 issue of JAMA, Samuel Frank, M.D., of Harvard Medical School, Boston, and the Huntington Study Group, and colleagues evaluated the efficacy and safety of the drug deutetrabenazine to control a prominent symptom of Huntington disease, chorea, which is an involuntary, sudden movement that can affect any muscle and flow randomly across body regions. Chorea can interfere with daily functioning and increase the risk of injury.

The drug tetrabenazine is the only U.S. Food and Drug Administration-approved therapy for treating chorea associated with Huntington disease. Despite established efficacy, tetrabenazine often requires 3-times-a-day dosing, and there may be some peak concentration-related neuropsychiatric symptoms, such as sedation, fatigue, anxiety or nausea. For this study, 90 adults diagnosed with Huntington disease and a certain level of chorea were randomly assigned to receive deutetrabenazine (n = 45) or placebo (n = 45). Deutetrabenazine or placebo was titrated to optimal dose level over 8 weeks and maintained for 4 weeks.

The researchers found that deutetrabenazine treatment significantly improved chorea control as measured by a chorea score. Significant improvement was also observed on measures of impression of change and physical functioning, although no improvement was observed on a balance test. Adverse event rates were similar for deutetrabenazine and placebo, including depression, anxiety and akathisia (a movement disorder).

The authors note that the difference in total maximal chorea score associated with deutetrabenazine treatment that was observed in this study is notable given the progressive decline in total maximal chorea score and total motor score that has been previously described as part of the natural history of Huntington disease.

"Further research is needed to assess the clinical importance of the effect size and to determine longer-term efficacy and safety."


Story Source:

Materials provided by JAMA - Journal of the American Medical Association. Note: Content may be edited for style and length.


Journal Reference:

  1. Samuel Frank, M.D. et al. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA, June 2016 DOI: 10.1001/jama.2016.8655

Cite This Page:

JAMA - Journal of the American Medical Association. "Drug helps control involuntary, sudden movements of Huntington disease." ScienceDaily. ScienceDaily, 5 July 2016. <www.sciencedaily.com/releases/2016/07/160705112132.htm>.
JAMA - Journal of the American Medical Association. (2016, July 5). Drug helps control involuntary, sudden movements of Huntington disease. ScienceDaily. Retrieved May 8, 2017 from www.sciencedaily.com/releases/2016/07/160705112132.htm
JAMA - Journal of the American Medical Association. "Drug helps control involuntary, sudden movements of Huntington disease." ScienceDaily. www.sciencedaily.com/releases/2016/07/160705112132.htm (accessed May 8, 2017).